These low levels of METTL14 and ZC3H13 are negatively correlated with overall survival (OS) and progression-free survival (PFS) in luminal type A, luminal type B, human epidermal growth factor receptor 2 (HER2)-enriched type, and triple-negative-type breast cancer, indicating that the reduced expression of METTL14 and ZC3H13 leads to poor prognosis in breast cancer patients (Gong et al., 2020). The gene discussed is METTL14; the disease is breast carcinoma.